Effect of RAS mutations and related immune characteristics on the prognosis of patients with MSI-H/dMMR colorectal cancer

被引:0
|
作者
Jiang, Yupeng [1 ]
Liu, Yuyao [2 ]
Huang, Hong [3 ]
Zhao, Tiantian [1 ]
Zhao, Zengyi [1 ]
Gao, Yawen [1 ]
机构
[1] Cent South Univ, Xiangya Hosp 2, Dept Oncol, Changsha 410011, Hunan, Peoples R China
[2] Univ South China, Affiliated Changsha Cent Hosp, Hengyang Med Sch, Dept Oncol, Changsha 410004, Peoples R China
[3] Guilin Med Univ, Guilin 541000, Peoples R China
关键词
RAS mutation; High microsatellite instability; Deficient mismatch repair; Colorectal cancer; Tumor microenvironment; TUMOR-INFILTRATING LYMPHOCYTES; MISMATCH REPAIR-DEFICIENT; DENDRITIC CELLS; MICROSATELLITE INSTABILITY; KRAS MUTATION; E-SELECTIN; OPEN-LABEL; MICROENVIRONMENT; PEMBROLIZUMAB; CHEMOTHERAPY;
D O I
10.1007/s00262-024-03926-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeMicrosatellite high instability/deficient mismatch repair (MSI-H/dMMR) colorectal cancer (CRC) has an active tumor microenvironment, rendering it more sensitive to immune checkpoint inhibitors. Given that studies involving patients with MSI-H colorectal cancer with RAS mutations are scarce, we explored the effect of RAS mutations on the TME in patients with MSI-H/dMMR cancer and identified potential prognostic factors.MethodsSeventy-five patients diagnosed with MSI-H/dMMR colorectal cancer were retrospectively enrolled and divided into RAS-mutant and -wild-type groups. The expression levels of CD11c+ dendritic cells, CD4+ T cells, CD8+ T cells, and regulatory T cell (Treg) markers were detected, and prognostic factors were analyzed.ResultsRAS-mutant MSI-H colorectal patients were more likely to have: (1) higher platelet values; (2) shorter disease-free survival (DFS); (3) lower infiltrated numbers of CD11c+ dendritic cells, CD4+ T lymphocytes, and CD8+ T lymphocytes, and higher infiltrated numbers of Foxp3+ Treg cells. In MSI-H/dMMR CRC patients: (1) the high CD11c + , CD4 +, and CD8 + cells infiltration group had longer DFS than the low-infiltration group, and Foxp3 + cells infiltration was not significantly correlated with DFS; (2) the RAS mutation status, number of CD11c+ cells infiltrated, and carbohydrate antigen 19-9 (CA19-9) level were the potential prognostic factors.ConclusionRAS mutations in patients with MSI-H/dMMR CRC may reduce the infiltration of CD11c+ dendritic cells, CD4+ T cells, and CD8+ T cells, and increase the infiltration of Foxp3+ Treg cells to affect the tumor microenvironment of patients. RAS gene status, CD11c + cells infiltration, and CA19-9 level were potential prognostic factors for MSI-H/dMMR CRC.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Natural history and patterns of progression for dMMR/MSI-H colorectal cancer treated with immune checkpoint blockade: A single center retrospective analysis.
    Higbie, Victoria
    Shah, Preksha
    Bent, Alisha Heather
    Dasari, Arvind
    Huey, Ryan W.
    Johnson, Benny
    Kee, Bryan K.
    Kopetz, Scott
    Lee, Michael Sangmin
    Ludford, Kaysia
    Morelli, Maria Pia
    Morris, Van K.
    Parseghian, Christine Megerdichian
    Raghav, Kanwal Pratap Singh
    Shen, John Paul Y. C.
    Willis, Jason
    Wolff, Robert A.
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 145 - 145
  • [42] Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience
    Higbie, Victoria Serpas
    Rogers, Jane
    Hwang, Hyunsoo
    Qiao, Wei
    Xiao, Lianchun
    Dasari, Arvind
    Mola-Rudd, Kerri
    Morris, Van K.
    Wolff, Robert A.
    Raghav, Kanwal
    Huey, Ryan
    Parseghian, Christine
    Willis, Jason
    Kopetz, Scott
    Overman, Michael J.
    Johnson, Benny
    ONCOLOGIST, 2022, 27 (11): : 952 - 957
  • [43] The controversial abscopal effect: A single-center experience about the combination of stereotactic radiotherapy with pembrolizumab in patients with metastatic dMMR/MSI-H colorectal cancer
    Gandini, Annalice
    Martelli, Valentino
    Belgioia, Liliana
    Puglisi, Silvia
    Cremante, Malvina
    Murianni, Veronica
    Damassi, Alessandra
    Ricciotti, Ilaria
    Pirrone, Chiara
    Catalano, Fabio
    Grassi, Massimiliano
    Pessino, Anna Maria
    Pastorino, Alessandro
    Sciallero, Stefania
    Puccini, Alberto
    Sobrero, Alberto F.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer
    Bui, Quang Loc
    Mas, Leo
    Hollebecque, Antoine
    Tougeron, David
    de la Fouchardiere, Christelle
    Pudlarz, Thomas
    Alouani, Emily
    Guimbaud, Rosine
    Taieb, Julien
    Andre, Thierry
    Colle, Raphael
    Cohen, Romain
    CANCERS, 2022, 14 (02)
  • [45] Genomic evolutionary mechanisms in MSI-H colorectal cancer
    Kobayashi, Yuta
    Niida, Atsushi
    Haeno, Hiroshi
    Masuda, Takaaki
    Doki, Yuichiro
    Eguchi, Hidetoshi
    Shibata, Tatsuhiro
    Mimori, Koshi
    CANCER SCIENCE, 2025, 116 : 775 - 775
  • [46] Nivolumab plus ipilimumab for MSI-H colorectal cancer
    不详
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (02): : 112 - 112
  • [47] Real-world treatment patterns and unmet need in patients with previously treated metastatic colorectal cancer that is not MSI-H or dMMR.
    Desai, Kaushal
    Sura, Sneha
    Liu, Zhimei
    Amonkar, Mayur
    Jain, Rishi
    Niehoff, Nicole
    Wilson, Thomas W.
    Patton, Gregory A.
    Cosgrove, David
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 53 - 53
  • [48] Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancers
    Wang, Zhenghang
    Cheng, Siyuan
    Yao, Yanhong
    Liu, Shengde
    Liu, Zimin
    Liu, Ning
    Jin, Yongdong
    Zhang, Yinjie
    Yin, Fei
    Han, Guangjie
    Zhang, Jingdong
    Wang, Qiwei
    Yan, Dong
    Wang, Li
    Lu, Hongxia
    Deng, Ting
    Ji, Zhi
    Gao, Hui
    Fang, Weijia
    Zhang, Hangyu
    Chen, Zhiyu
    Zou, Jianling
    Tang, Yong
    Xu, Chunlei
    Li, Jiayi
    Qu, Huajun
    Bao, Liying
    Cao, Baoshan
    Wang, Xicheng
    Xu, Ting
    Sun, Yu
    Shen, Lin
    Peng, Zhi
    Li, Jian
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (09)
  • [49] Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer
    Oliveira, Andre F.
    Bretes, Luis
    Furtado, Irene
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [50] Case report: Efficacy of immunotherapy as conversion therapy in dMMR/MSI-H colorectal cancer: a case series and review of the literature
    San-Roman-Gil, Maria
    Martinez-Delfrade, Inigo
    Albarran-Fernandez, Victor
    Guerrero-Serrano, Patricia
    Pozas-Perez, Javier
    Chamorro-Perez, Jesus
    Rosero-Rodriguez, Diana
    Sotoca-Rubio, Pilar
    Barrill-Corpa, Ana Maria
    Alia-Navarro, Victor
    Gonzalez-Merino, Carlos
    Garcia-de-Quevedo-Suero, Coral
    Lopez, Victoria
    Ruz-Caracuel, Ignacio
    Perna-Monroy, Cristian
    Ferreiro-Monteagudo, Reyes
    FRONTIERS IN IMMUNOLOGY, 2024, 15